Application of peripheral blood mononuclear cell activation inhibitors to preparing medicines for treating acute hepatic failure

Abstract

The invention discloses application of peripheral blood mononuclear cell activation inhibitors to preparing a medicine for treating and / or preventing acute hepatic failure, and further provides the medicine for treating and / or preventing the acute hepatic failure. The medicine is a preparation, the peripheral blood mononuclear cell activation inhibitors are used as active substances for the preparation, and pharmacologically acceptable excipients or auxiliary components are added into the peripheral blood mononuclear cell activation inhibitors to prepare the preparation. The application and the medicine have the advantages that the fact that activation of mononuclear cells can be effectively inhibited is proved, accordingly, acute hepatic injury can be effectively treated and prevented, a novel option can be provided for clinically treating the acute hepatic injury, and the medicine has an excellent application prospect.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the use of an inhibitor of peripheral blood mononuclear cell activation in the preparation of medicines for treating acute liver failure. Background technique [0002] Acute liver failure (ALF) has sudden onset, high mortality and great harm. In developed countries, the incidence of ALF is less than 10 per million, but in developing countries including China, despite the lack of accurate data, the incidence of ALF is obviously much higher. In 2013, Bernal W et al published a review in the "New England Journal of Medicine", which followed the definition of ALF proposed in 1970: severe, potentially reversible liver damage without underlying liver disease, which occurs within 8 weeks after the first symptoms. encephalopathy. According to the interval between the first symptom and hepatic encephalopathy, it can be divided into hyperacute, acute, subacute, and so on. Afterwards,...

AI Technical Summary

Problems solved by technology

Tissue engineered liver, bioartificial liver, and hepatocyte transplantation may be effective for ALF, but the technology is still immature, and there is a lack of sufficient clinical case accumulation and evidence-based medical evidence, especially the lack of large-scale randomized clinical trials, so it is still difficult to be used as a routine treatment. The treatment of ALF is still a worldwide problem

Images